Moloney Securities Asset Management LLC bought a new stake in NeoGenomics, Inc. (NASDAQ:NEO) during the third quarter, HoldingsChannel.com reports. The fund bought 14,089 shares of the medical research company’s stock, valued at approximately $269,000.

Several other hedge funds have also recently modified their holdings of the company. LPL Financial LLC raised its holdings in shares of NeoGenomics by 2.4% in the 2nd quarter. LPL Financial LLC now owns 19,250 shares of the medical research company’s stock valued at $422,000 after purchasing an additional 455 shares during the period. Municipal Employees Retirement System of Michigan grew its stake in NeoGenomics by 1.6% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 30,870 shares of the medical research company’s stock valued at $590,000 after buying an additional 490 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in NeoGenomics by 14.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,778 shares of the medical research company’s stock valued at $110,000 after buying an additional 739 shares during the last quarter. Yorktown Management & Research Co Inc grew its stake in NeoGenomics by 4.6% in the 2nd quarter. Yorktown Management & Research Co Inc now owns 18,300 shares of the medical research company’s stock valued at $402,000 after buying an additional 800 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its stake in NeoGenomics by 3.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 25,647 shares of the medical research company’s stock valued at $562,000 after buying an additional 945 shares during the last quarter. 85.02% of the stock is currently owned by institutional investors.

In other news, insider Robert J. Shovlin sold 70,473 shares of the firm’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $23.11, for a total transaction of $1,628,631.03. Following the completion of the transaction, the insider now owns 251,914 shares of the company’s stock, valued at $5,821,732.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Bonello sold 17,000 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $24.83, for a total transaction of $422,110.00. Following the transaction, the insider now directly owns 23,735 shares of the company’s stock, valued at approximately $589,340.05. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 311,843 shares of company stock worth $7,646,311. Company insiders own 8.80% of the company’s stock.

Shares of NASDAQ:NEO traded up $0.64 on Friday, reaching $22.65. 7,563 shares of the company’s stock were exchanged, compared to its average volume of 655,726. The company has a fifty day moving average of $20.66 and a 200-day moving average of $22.50. NeoGenomics, Inc. has a twelve month low of $11.05 and a twelve month high of $26.89. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of 171.69 and a beta of 0.94. The company has a current ratio of 4.24, a quick ratio of 4.05 and a debt-to-equity ratio of 0.24.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, October 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.01. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The firm had revenue of $104.70 million for the quarter, compared to analyst estimates of $99.38 million. During the same quarter in the prior year, the business posted $0.05 EPS. The business’s revenue was up 51.5% compared to the same quarter last year. As a group, equities research analysts forecast that NeoGenomics, Inc. will post 0.19 EPS for the current fiscal year.

NEO has been the topic of a number of research reports. ValuEngine upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Benchmark set a $27.00 price target on shares of NeoGenomics and gave the company a “buy” rating in a research note on Wednesday, July 31st. Needham & Company LLC upped their price target on shares of NeoGenomics from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Raymond James upped their price target on shares of NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, July 31st. Finally, Leerink Swann set a $30.00 price target on shares of NeoGenomics and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $24.86.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Story: Ex-Dividend

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.